60 Degrees Pharmaceuticals, Inc. (SXTP)
NASDAQ: SXTP · IEX Real-Time Price · USD
0.271
+0.025 (10.16%)
At close: Jul 19, 2024, 4:00 PM
0.236
-0.035 (-12.92%)
Pre-market: Jul 22, 2024, 9:01 AM EDT
SXTP Employees
60 Degrees Pharmaceuticals had 3 employees as of December 31, 2023. The number of employees increased by 1 or 50.00% compared to the previous year.
Employees
3
Change (1Y)
1
Growth (1Y)
50.00%
Revenue / Employee
$189,954
Profits / Employee
-$338,048
Market Cap
3.31M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 3 | 1 | 50.00% |
| Dec 31, 2022 | 2 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Xylo Technologies | 84 |
| Avinger | 72 |
| Aditxt | 47 |
| Aptevo Therapeutics | 40 |
| Healthcare Triangle | 31 |
| Ensysce Biosciences | 7 |
| ZyVersa Therapeutics | 7 |
| Qualigen Therapeutics | 4 |
SXTP News
- 3 days ago - 60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study - GlobeNewsWire
- 13 days ago - 60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment - GlobeNewsWire
- 25 days ago - First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind - GlobeNewsWire
- 7 weeks ago - Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind - GlobeNewsWire
- 2 months ago - 60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study - GlobeNewsWire
- 2 months ago - 60 Degrees Pharmaceuticals Announces First Quarter 2024 Results - GlobeNewsWire
- 2 months ago - 60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases - GlobeNewsWire
- 2 months ago - 60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required - GlobeNewsWire